CGEN-15001T is the internal designation for ILDR2, a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen.
Studies testing the immune function of CGEN-15001T/ILDR2, as a membrane bound protein or using a recombinant fusion protein containing the extracellular domain of CGEN-15001T/ILDR2, showed it is capable of inhibiting T cell activation, promoting a Th1 to Th2 shift, and potentially inducing immune tolerance. CGEN-15001T/ILDR2 is expressed in subpopulations of immune cells, mainly macrophages, in both tumor and normal tissue samples.
In August 2013, Compugen signed a research and discovery collaboration and license agreement with Bayer HealthCare for the development and commercialization of antibody-based therapeutics for cancer immunotherapy against CGEN-15001T/ILDR2. After achieving all preclinical stage milestones, this program was transferred to Bayer for further development. To date, preclinical activities are on track, and pivotal toxicity studies and GMP clinical trial material production are ongoing.